title: Cereport (RMP-7) increases carboplatin levels in brain tumors after pretreatment with dexamethasone.
abstract: Accumulating evidence suggests that dexamethasone might decrease permeability of the blood-brain tumor barrier, further limiting the delivery of agents into brain tumors. The bradykinin B2 receptor agonist, Cereport (RMP-7), selectively increases permeability of the vasculature supplying brain tumors in both animal models and humans. The present study was conducted to characterize the effects of dexamethasone on the blood-brain tumor barrier and its potential interaction with Cereport's ability to enhance penetration of radiolabeled carboplatin. Dexamethasone (1.5 mg/kg/day, twice a day) was given to RG2 glioma-bearing rats via oral gavage for 3 consecutive days. After treatment, animals received a 15-min intracarotid infusion of Cereport (4.5 micrograms/kg) and a bolus of [14C]carboplatin. The levels of [14C]carboplatin (nCi/g) in the tumor and nontumor regions were determined at 1, 14, or 24 h after the last dose of dexamethasone. Dexamethasone, alone, significantly decreased the levels of radiolabeled carboplatin permeating the tumor (19%), although there were no significant differences between any of the time points examined. Cereport administration significantly increased levels of carboplatin in the tumor, independent of whether or not dexamethasone was given (46% with and 49% without). Although the relative effects of Cereport on tumor carboplatin levels were not affected by dexamethasone, the absolute levels achieved with Cereport were modestly reduced (44 nCi/g versus 55.5 nCi/g of [14C]carboplatin, with and without dexamethasone, respectively). Thus, while the data support the use of Cereport as adjunctive therapy in the treatment of glioma patients, they also warn that the use of dexamethasone may reduce delivery of chemotherapeutic agents to brain tumors, even when special pharmacologic measures are employed to enhance delivery.
authors.affiliation: Alkermes, Inc., 64 Sidney St., 4th Floor, Cambridge, MA 02139, USA.
authors.forename: R L
authors.initials: RL
authors.lastname: Dean
authors.forename: D F
authors.initials: DF
authors.lastname: Emerich
authors.forename: B P
authors.initials: BP
authors.lastname: Hasler
authors.forename: R T
authors.initials: RT
authors.lastname: Bartus
mesh_terms: D000818:Animals; D001812:Blood-Brain Barrier / Q000187:drug effects*; D001835:Body Weight / Q000187:drug effects; D001920:Bradykinin / Q000031:analogs & derivatives / Q000494:pharmacology*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D016190:Carboplatin / Q000493:pharmacokinetics*; D003864:Depression, Chemical; D003907:Dexamethasone / Q000494:pharmacology*; D004334:Drug Administration Schedule; D005910:Glioma / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D009368:Neoplasm Transplantation; D009929:Organ Size / Q000187:drug effects; D010539:Permeability / Q000187:drug effects; D051381:Rats; D011916:Rats, Inbred F344; D043782:Receptor, Bradykinin B2; D018002:Receptors, Bradykinin / Q000819:agonists*; D014407:Tumor Cells, Cultured
chemical_list: D043782:Receptor, Bradykinin B2; D018002:Receptors, Bradykinin; C089876:RMP 7; D003907:Dexamethasone; D016190:Carboplatin; D001920:Bradykinin